Surmodics, Inc. – NASDAQ:SRDX
Surmodics stock price today
$37.34
-2.09
-5.32%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 21 minutes
Surmodics stock price monthly change
-6.47%
month
Surmodics stock price quarterly change
-6.47%
quarter
Surmodics stock price yearly change
+6.57%
year
Surmodics key metrics
Market Cap | 565.76M |
Enterprise value | 337.67M |
P/E | -10.13 |
EV/Sales | 3.31 |
EV/EBITDA | -20.09 |
Price/Sales | 3.23 |
Price/Book | 3.07 |
PEG ratio | 0.01 |
EPS | 0.46 |
Revenue | 139.60M |
EBITDA | 24.09M |
Income | 6.55M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -31.71% |
Oper. margin | -25.4% |
Gross margin | 28.54% |
EBIT margin | -25.4% |
EBITDA margin | 17.26% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSurmodics stock price history
Surmodics stock forecast
Surmodics financial statements
| Mar 2023 | 27.19M | -7.73M | -28.43% |
|---|---|---|---|
| Jun 2023 | 52.48M | 7.34M | 14% |
| Sep 2023 | 27.97M | 6.69M | 23.93% |
| Mar 2024 | 31.95M | 247K | 0.77% |
| Sep 2025 | 35.35M | 980.55K | 2.77% |
|---|---|---|---|
| Oct 2025 | 35.28M | 691.01K | 1.96% |
| Dec 2025 | 35.00M | -1.22M | -3.5% |
| Mar 2026 | 32.92M | -2.10M | -6.39% |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 166163000 | 63.60M | 38.28% |
|---|---|---|---|
| Jun 2023 | 188901000 | 76.48M | 40.49% |
| Sep 2023 | 185733000 | 65.82M | 35.44% |
| Mar 2024 | 182805000 | 58.85M | 32.2% |
| Mar 2023 | -5.82M | -723K | -794K |
|---|---|---|---|
| Jun 2023 | 25.89M | -470K | -19K |
| Sep 2023 | 1.25M | -4.65M | 419K |
| Mar 2024 | 7.41M | 2.79M | -405K |
Surmodics alternative data
| Aug 2023 | 447 |
|---|---|
| Sep 2023 | 447 |
| Oct 2023 | 447 |
| Nov 2023 | 447 |
| Dec 2023 | 376 |
| Jan 2024 | 376 |
| Feb 2024 | 376 |
| Mar 2024 | 376 |
| Apr 2024 | 376 |
| May 2024 | 376 |
| Jun 2024 | 376 |
| Jul 2024 | 376 |
Surmodics other data
47.05%
-45.22%
of SRDX is owned by hedge funds
68
-49
6.57M
-6.26M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2024 | 0 | 7009 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | ARENS TIMOTHY J. officer: Chief Fi.. | Common Stock | 7,009 | $39.44 | $276,456 | ||
Option | STICH JOSEPH J. officer: SVP of H.. | Common Stock | 21,285 | $33.2 | $706,662 | ||
Option | STICH JOSEPH J. officer: SVP of H.. | Employee Stock Option (right to buy) | 21,285 | $33.2 | $706,662 | ||
Option | MAHARAJ GARY R director, officer.. | Common Stock | 61,017 | $33.2 | $2,025,764 | ||
Option | MAHARAJ GARY R director, officer.. | Employee Stock Option (right to buy) | 61,017 | $33.2 | $2,025,764 | ||
Option | OLSON CHARLES W officer: SVP, Medical Device Co.. | Common Stock | 18,447 | $33.2 | $612,440 | ||
Option | OLSON CHARLES W officer: SVP, Medical Device Co.. | Employee Stock Option (right to buy) | 18,447 | $33.2 | $612,440 | ||
Option | ARENS TIMOTHY J. officer: Chief Fi.. | Common Stock | 18,447 | $33.2 | $612,440 | ||
Option | ARENS TIMOTHY J. officer: Chief Fi.. | Employee Stock Option (right to buy) | 18,447 | $33.2 | $612,440 | ||
Option | BEDOYA JOSE H director | Common Stock | 3,932 | $23.95 | $94,171 |
| Patent |
|---|
Application Filling date: 7 Jan 2022 Issue date: 14 Jul 2022 |
Application Filling date: 21 Mar 2022 Issue date: 7 Jul 2022 |
Grant Utility: Hemodialysis catheter sleeve Filling date: 15 Nov 2019 Issue date: 12 Apr 2022 |
Grant Filling date: 30 Mar 2017 Issue date: 22 Mar 2022 |
Grant Filling date: 16 May 2014 Issue date: 15 Feb 2022 |
Grant Design: Helical strain relief device Filling date: 28 Feb 2020 Issue date: 4 Jan 2022 |
Grant Filling date: 8 Jul 2019 Issue date: 16 Nov 2021 |
Application Filling date: 5 Jun 2019 Issue date: 28 Oct 2021 |
Grant Filling date: 14 Dec 2017 Issue date: 21 Sep 2021 |
Application Filling date: 10 May 2021 Issue date: 26 Aug 2021 |
| Quarter | Transcript |
|---|---|
| Q2 2024 1 May 2024 | Q2 2024 Earnings Call Transcript |
| Q1 2024 1 Feb 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 10 Nov 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Aug 2023 | Q3 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Gary R. Maharaj (1963) Chief Executive Officer, Pres & Director | $1,290,000 |
Ms. Teryl L. W. Sides (1970) Senior Vice President of Product Devel. & Chief Marketing Officer | $638,670 |
| Mr. Gordon S. Weber (1963) Senior Vice President of Legal, Gen. Counsel & Sec. | $573,670 |
| Mr. Timothy J. Arens (1967) Senior Vice President of Fin. & Information Technology and Chief Financial Officer | $572,000 |
| Mr. Joseph J. Stich (1965) Senior Vice President and GM of HR & In Vitro Diagnostics | $570,920 |
-
What's the price of Surmodics stock today?
One share of Surmodics stock can currently be purchased for approximately $37.34.
-
When is Surmodics's next earnings date?
Unfortunately, Surmodics's (SRDX) next earnings date is currently unknown.
-
Does Surmodics pay dividends?
No, Surmodics does not pay dividends.
-
How much money does Surmodics make?
Surmodics has a market capitalization of 565.76M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 4.91% to 126.08M US dollars.
-
What is Surmodics's stock symbol?
Surmodics, Inc. is traded on the NASDAQ under the ticker symbol "SRDX".
-
What is Surmodics's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Surmodics?
Shares of Surmodics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Surmodics's key executives?
Surmodics's management team includes the following people:
- Mr. Gary R. Maharaj Chief Executive Officer, Pres & Director(age: 62, pay: $1,290,000)
- Ms. Teryl L. W. Sides Senior Vice President of Product Devel. & Chief Marketing Officer(age: 55, pay: $638,670)
- Mr. Gordon S. Weber Senior Vice President of Legal, Gen. Counsel & Sec.(age: 62, pay: $573,670)
- Mr. Timothy J. Arens Senior Vice President of Fin. & Information Technology and Chief Financial Officer(age: 58, pay: $572,000)
- Mr. Joseph J. Stich Senior Vice President and GM of HR & In Vitro Diagnostics(age: 60, pay: $570,920)
-
How many employees does Surmodics have?
As Jul 2024, Surmodics employs 376 workers.
-
When Surmodics went public?
Surmodics, Inc. is publicly traded company for more then 27 years since IPO on 4 Mar 1998.
-
What is Surmodics's official website?
The official website for Surmodics is surmodics.com.
-
Where are Surmodics's headquarters?
Surmodics is headquartered at 9924 West 74th Street, Eden Prairie, MN.
-
How can i contact Surmodics?
Surmodics's mailing address is 9924 West 74th Street, Eden Prairie, MN and company can be reached via phone at +95 2 500 7000.
Surmodics company profile:
Surmodics, Inc.
surmodics.comExchange:
NASDAQ
Full time employees:
376
Industry:
Medical - Devices
Sector:
Healthcare
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
9924 West 74th Street
Eden Prairie, MN 55344-3523
Eden Prairie, MN 55344-3523
CIK: 0000924717
ISIN: US8688731004
CUSIP: 868873100
